Article
Pharmaceutical Executive
Author(s):
Only a year ago, hopes were high of rapid progress towards a transatlantic trade deal that would boost the European and US economies - and ease conditions for drug firms on both sides of the ocean.
Only a year ago, hopes were high of rapid progress towards a transatlantic trade deal that would boost the European and US economies - and ease conditions for drug firms on both sides of the ocean. TTIP, the Transatlantic Trade and Investment Partnership, was the hot tip for a 2014 success story. But as summer slides away and autumn beckons, the latest read-out of progress suggests that rather than remaining a hot tip, TTIP now risks being tipped into oblivion.
For the rest of this article, click here.
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.